“Asthma and COPD inhalers delivering fixed-dose combinations of inhaled corticosteroid (ICS) and long-acting beta agonists (LABA) drugs will no longer be required to carry a boxed warning about the possibility of asthma-related death associated with their use, the FDA said late Wednesday”, stated the article posted by Medpage Today.
“We have never had an issue with these medications as the data has always suggested that the warning was uncalled for and related to study design during an era where controller therapies were not the routine. We certainly applaud this decision by the FDA”, says Dr. Jain.
To read the full article posted by Medpage Today, click here.
